Prognostic Roles of C-Reactive Protein and Erythrocyte Sedimentation Rate As Acute Phase Reactants in Mentally Challenged Subjects


Background: A mental disorder is a psychiatric disease that presents as mild or severe disturbances in a person’s behavior, mood, or thought. Mental illnesses are very common because of excessive stress. Recent studies show that mental illnesses are on the rise generally because of increasing stress. In Nigeria, medical records suggest an upsurge in mental health cases since the onset of the country’s economic downturn and the consequent trauma following it. The erythrocyte sedimentation rate (ESR) is an indirect marker of serum acute-phase protein concentrations, whereas C-reactive protein (CRP) is a direct protein measurement and it is inherently more well-defined. This study thus evaluated the roles of ESR and CRP as sensitive markers of inflammation and correlated their levels with severity stratification and prognosis in schizophrenic patients.

Materials and Methods: This is a case-control study, and it was carried out on 40 patients diagnosed with schizophrenia. Thirty (30) controls were matched for age and sex; 8 millimeters of venous blood was collected from each participant using ante-cubital veins. Samples collected were dispensed into appropriate bottles for
analysis of CRP and hematological parameters using standard laboratory procedures. Statistical analysis of the data was done appropriately and P-value of less than 0.05 was considered as significant.

Results: At the end of the study, the mean granulocytes, ESR, and CRP were significantly higher in schizophrenia cases than in the controls, while the mean PCV, RBC, and hemoglobin were significantly lower in the subjects. CRP had a higher area than ESR under the ROC curve (AUROC).

Conclusion: This study thus evaluated the role of ESR and CRP as sensitive markers of inflammation and acute phase reactants in schizophrenic patients. The findings showed that CRP was a better diagnostic or predictor treatment outcome of schizophrenia.

[1] Gonzalez-Liencres, C., Tas, C., Brown, E. C., et al. (2014). Oxidative stress in schizophrenia: A case-control study on the effects on social cognition and neurocognition. BMC Psychiatry, vol. 14, p. 268. Retrieved from

[2] Opler, M., Charap, J., Greig, A., et al. (2013). Environmental risk factors and schizophrenia. International Journal of Mental Health, vol. 42, no. 1, pp. 23–32. Retrieved from

[3] Brown, A. S. (2006). Prenatal infection as a risk factor for schizophrenia. Schizophrenia Bulletin, vol. 32, pp. 200–202.

[4] Van, O. S. and Kapur, S. (2009). Schizophrenia. Lancet, vol. 374, no. 9690, pp. 635– 645. DOI: 10.1016/S0140-6736(09)60995-8.

[5] Akinlade, K. S., Fagbomedo, F. O., and Rahamon, S. K. (2014). Serum copeptin and its diagnostic performance in schizophrenia. African Journal of Medical Sciences, vol.43, pp. 259–264.

[6] Adegbaju, D. 1.7 million Nigerians have schizophrenia. Speech delivered by Dr. Dapo Adegbaju, a Consultant Psychiatrist at the Federal Neuro-Pschiatric Hospital, Yaba to mark the 2014 World Mental Health Day.

[7] Sandra, S. (1997). Depression: Questions You Have - Answers You Need. People’s Medical Society

[8] Abas, M. and Broadhead, J. (2001). Mental disorders in the developing world. British Medical Journal, vol. 308, p. 1052.

[9] Patel, V., Gwanzura, F., Simunyu, E., et al. (2001). The explanatory models and phenomenology of common mental disorder in Harare, Zimbabwe. Psychological Medicine, vol. 25, pp. 1191–1199.

[10] Beers, M. H., Fletscher, A. J., Jones, T. V., et al. (2005). Merck Manual. Houten: Bohn Stafleu van Loghum.

[11] Bahn, S., Guest, P., Harris, L., et al. Biomarkers for schizophrenia. Patent no: WO 2011121361A1. Filling date March 31, 2011.

[12] Akinlade, K. S., Atere, A. D., Olaniyi, J. A., et al. (2013). Serum copeptin and cortisol do not accurately predict sickle cell anaemia vaso-occlusive crisis as C-reactive protein. PLoS One, vol. 8, no. 11, e77913.

[13] Kawai, N., Baba, A., Suzuki, T., et al. (2001). Roles of arginine vasopressin and atrial natriuretic peptide in polydipsia-hyponatremia of schizophrenic patients. Psychiatry Research, vol. 101, no. 1, pp. 39–45.

[14] Katan, M., Nigro, N., Fluri, F., et al. (2011). Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology, vol. 76, no. 6, pp. 563–566.

[15] Ceron, J. J., Eckersall, P. D., and Martynez-Subiela, S. (2005). Acute phase proteins in dogs and cats: Current knowledge and future perspectives. Veterinary Clinical Pathology, vol. 34, pp. 85–99.

[16] Ridker, P. M., Danielson, E., and Fonseca, F. A. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, vol. 359, pp. 195–207.

[17] Schunkert, H. (2008). Elevated C-reactive protein in Atherosclerosis – Chicken or Egg? The New England Journal of Medicine, vol. 359, p. 18.

[18] Pearson, T. (2003). Markers of inflammation and cardiovascular disease. AHA/CDC Scientific Statement. Circulation, vol. 107, p. 499.

[19] Zacho, J., Hansen, A. T., Jensen, J. S., et al. (2008). Genetically elevated C-reactive protein and ischemic vascular disease. The New England Journal of Medicine, vol. 359, pp. 1897–1908.

[20] Stolz, D., Christ-Crain, M., Morgenthaler, N. G., et al. (2007). Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, vol. 131, no. 4, pp. 1058–1067.

[21] Calderon, A. J. and Wener, M. H. (2012). Erythrocyte sedimentation rate and Creactive protein. Hospital Medicine Clinics, vol. 1, pp. 313–337.

[22] Stefanović, V., Mihajlović, G., Nenadović, M., et al. (2015). The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. Vojnosanitetski Pregled, vol. 72, no. 12, pp. 1085–1092. DOI: 10.2298/VSP140526016S.

[23] Johnson, H. L., Chiou, C. C., and Cho, C. T. (1999). Applications of acute phase reactants in infectious diseases. Journal of Microbiology, Immunology and Infection, vol. 32, no. 2, pp. 73–82.

[24] Wang, Z., Li, P., Chi, D., et al. (2017). Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis. Oncotarget, vol. 8, no. 43, pp. 75445– 75454.

[25] Miller, B. J., Buckley, P., Seabolt, W., et al. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic eects. Biological Psychiatry, vol. 70, pp. 663–671.

[26] Boll, K. M., Noto, C., Bonifácio, B. L., et al. (2017). Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Research, vol. 253, pp. 43–48.

[27] Pavlovic, M., Babic, D., Rastovic, P., et al. (2013). Association of erythrocyte sedimentation rate and fibrinogen concentration with metabolic syndrome in a schizophrenic patients. Psychiatria Danubina, vol. 25, no. 1, pp. 51–55.

[28] Melamed, Y. and Sirota, P. (2000). Erythrocyte sedimentation rate in patients with schizophrenia. The Canadian Journal of Psychiatry, vol. 45, no. 10, p. 938.

[29] Richard, M. D. and Brahm, N. C. (2012). Schizophrenia and the immune system: Pathophysiology, prevention, and treatment. American Journal of Health-system Pharmacy, vol. 69, pp. 757–766.

[30] Najjar, S., Pearlman, D. M., Devinsky, O., et al. (2013). Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: A review of clinical and experimental evidence. Journal of Neuroinflammation, vol. 10, p. 142.